1 / 22

Table of Content - Global Blood and Plasma Components Market

The Blood and Plasma Components Market size in 2020 was $39.58 billion and is expected to reach $66.47 billion in 2031, growing at a CAGR of 4.90% over the forecast period 2021-2031.<br>

bisreports
Download Presentation

Table of Content - Global Blood and Plasma Components Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. res Blood and Plasma Components Market - A Global and Regional Analysis Table of Content GLOBAL BLOOD AND PLASMA COMPONENTS MARKET Focus on Product, Application, End User and Region Analysis and Forecast: 2021-2031 April 2022 1 All rights reserved at BIS Research Inc.

  2. BIS Research is a leading market intelligence and technology research company. BIS Research publishes in- depth market intelligence reports focusing on the market estimations, technology analysis, emerging high- growth applications, deeply segmented granular country-level market data and other important market parameters useful in the strategic decision making for senior management. BIS Research provides multi-client reports, company profiles, databases, and custom research services. GLOBAL BLOOD AND PLASMA COMPONENTS MARKET Copyright © 2022 BIS Research Inc. All Rights Reserved. This document contains highly confidential information and is the sole property of BIS Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third party. 2 All rights reserved at BIS Research Inc.

  3. Table of Content Executive Summary .......................................................................... 26 1.Markets ..................................................................................... 33 1.1 Product Definition ............................................................................................ 34 1.1.1Inclusion and Exclusion Criteria ................................................................ 34 1.2 Market Scope ................................................................................................... 34 1.2.1Scope of the Study ...................................................................................... 34 1.2.2Key Questions Answered in the Report .................................................... 35 1.3 Research Methodology ................................................................................... 36 1.3.1Global Blood and Plasma Components Market: Research Methodology ................................................................................................ 36 1.3.2Data Sources ............................................................................................... 37 1.3.2.1 Primary Data Sources ........................................................................................ 37 1.3.2.2 Secondary Data Sources ................................................................................... 38 1.3.3Market Estimation Model ............................................................................ 39 1.3.4Criteria for Company Profiling ................................................................... 41 1.4 Market Overview .............................................................................................. 41 GLOBAL BLOOD AND PLASMA COMPONENTS MARKET 1.4.1Red Blood Cells ........................................................................................... 41 1.4.2Platelets ........................................................................................................ 42 1.4.3Plasma .......................................................................................................... 42 1.4.4Granulocytes ............................................................................................... 42 1.5 Historical Trends in the Use of Blood Components ..................................... 43 1.6 Use of Blood Components .............................................................................. 45 1.7 Market Footprint and Future Potential, $Million, 2020-2031 ......................... 46 2. Industry Analysis ...................................................................... 47 2.1 Overview ........................................................................................................... 48 2.2 Regulatory Framework .................................................................................... 48 3 All rights reserved at BIS Research Inc.

  4. 2.2.1Regulatory Framework in the U.S. ............................................................. 48 2.2.2Regulatory Framework in the European Union......................................... 50 2.2.3Regulatory Framework in Asia-Pacific ...................................................... 51 2.2.3.1 China ................................................................................................................. 51 2.2.3.2 Japan ................................................................................................................. 52 2.3 Supply Chain Analysis .................................................................................... 53 2.4 Impact of COVID-19 on Global Blood and Plasma Components Market ........................................................................................................................... 56 3. Market Dynamics ...................................................................... 58 3.1 Overview ........................................................................................................... 59 3.2 Impact Analysis ............................................................................................... 59 3.3 Market Drivers .................................................................................................. 60 3.3.1Global Increase in Patients with Blood Disorders .................................... 60 3.3.2Increase in Trauma Patients and Chronic Illnesses ................................. 61 3.3.3Rise in number of Product Launches and Approvals .............................. 62 3.4 Market Restraints ............................................................................................. 63 3.4.1Risk of Transfusion Transmitted Infectious Diseases and Adverse Reaction Associated with Blood Transfusion........................................... 63 GLOBAL BLOOD AND PLASMA COMPONENTS MARKET 3.4.2Long Duration of Manufacturing Process and Strict Regulatory Guidelines .................................................................................................... 65 3.5 Market Opportunities ....................................................................................... 67 3.5.1Increase in Adoption of Business Expansion Strategies in the Market ........................................................................................................... 67 4.Competitive Landscape ............................................................. 69 4.1 Overview ........................................................................................................... 70 4.2 Corporate Strategies ....................................................................................... 70 4.2.1Mergers and Acquisitions ........................................................................... 70 4.2.2Synergistic Activities .................................................................................. 71 4 All rights reserved at BIS Research Inc.

  5. 4.2.3Business Expansion, Funding, and Reimbursement Activities .............. 73 4.3 Business Strategies ........................................................................................ 74 4.3.1Product Launches ....................................................................................... 74 4.3.2Product Approvals ...................................................................................... 75 4.4 Market Share Analysis, by Company (2020) .................................................. 76 4.5 Growth-Share Analysis ................................................................................... 78 5.Products, $Million, 2020-2031 .................................................... 79 5.1 Overview ........................................................................................................... 80 5.2 Transfusion Market .......................................................................................... 81 5.2.1Packed Red Blood Cells ............................................................................. 82 5.2.2Platelet Products ......................................................................................... 83 5.2.3Frozen Plasma ............................................................................................. 85 5.3 Plasma-Derived Products ............................................................................... 86 5.3.1Immunoglobulins ......................................................................................... 88 5.3.1.1 Intravenous Immunoglobulins ............................................................................ 89 5.3.1.2 Subcutaneous Immunoglobulins ........................................................................ 91 5.3.1.3 Other Immunoglobulins ...................................................................................... 93 GLOBAL BLOOD AND PLASMA COMPONENTS MARKET 5.3.2Coagulation Factor Concentrates .............................................................. 95 5.3.2.1 Coagulation Factor VIII Concentrate ................................................................. 97 5.3.2.2 Coagulation Factor IX Concentrate ................................................................... 98 5.3.2.3 von Willebrand Factor (vWF) ........................................................................... 100 5.3.2.4 Prothrombin Complex Concentrates ................................................................ 101 5.3.2.5 Coagulation Factor XIII Concentrate ............................................................... 102 5.3.3Albumins .................................................................................................... 103 5.3.4Proteinase Inhibitors ................................................................................. 104 5.3.5Other Blood Derivatives ............................................................................ 105 6.Application, $Million, 2020-2031 ............................................... 106 5 All rights reserved at BIS Research Inc.

  6. 6.1 Overview ......................................................................................................... 107 6.2 Hematology .................................................................................................... 108 6.2.1Hemoglobinopathy .................................................................................... 109 6.2.1.1 Thalassemia .................................................................................................... 110 6.2.1.2 Sickle Cell Disease .......................................................................................... 112 6.2.1.3 Platelet Refractoriness ..................................................................................... 113 6.2.2Hematologic Malignancies Management ................................................. 114 6.2.3Coagulopathy ............................................................................................ 116 6.2.3.1 Hemophilia ....................................................................................................... 117 6.2.3.2 von Willebrand Disease ................................................................................... 119 6.2.3.3 Thrombosis ...................................................................................................... 121 6.2.3.4 Thrombocytopenia ........................................................................................... 123 6.3 Solid Tumor Management ............................................................................. 124 6.4 Others ............................................................................................................. 126 6.5 Emerging Areas of Application .................................................................... 126 7.End Users, $Billion, 202020-2031 ............................................. 128 7.1 Overview ......................................................................................................... 129 7.2 Hospitals and Specialty Clinics .................................................................... 130 GLOBAL BLOOD AND PLASMA COMPONENTS MARKET 7.3 Research Institutions .................................................................................... 131 7.4 Diagnostic Laboratories ................................................................................ 132 7.5 Other End Users ............................................................................................ 133 8.Region, $Million, 2020-2031 ..................................................... 135 8.1 Overview ......................................................................................................... 136 8.2 North America ................................................................................................ 138 8.2.1U.S. ............................................................................................................. 139 8.2.2Canada ....................................................................................................... 140 8.3 Europe ............................................................................................................ 141 6 All rights reserved at BIS Research Inc.

  7. 8.3.1Germany ..................................................................................................... 142 8.3.2U.K. ............................................................................................................. 143 8.3.3France ......................................................................................................... 145 8.3.4Italy ............................................................................................................. 146 8.3.5Spain ........................................................................................................... 147 8.3.6Rest-of-Europe........................................................................................... 148 8.4 Asia-Pacific .................................................................................................... 149 8.4.1China .......................................................................................................... 150 8.4.2India ............................................................................................................ 151 8.4.3Japan .......................................................................................................... 152 8.4.4Australia ..................................................................................................... 153 8.4.5South Korea ............................................................................................... 154 8.4.6Singapore ................................................................................................... 154 8.4.7Rest-of-Asia-Pacific ................................................................................... 155 8.5 Rest-of-the-World .......................................................................................... 156 9.Market – Competitive Benchmarking & Company Profiles ........ 158 9.1 Overview ......................................................................................................... 159 GLOBAL BLOOD AND PLASMA COMPONENTS MARKET 9.2 CSL Limited .................................................................................................... 161 9.2.1Company Overview ................................................................................... 161 9.2.2Role of CSL Limited in the Global Blood and Plasma Components Market ......................................................................................................... 161 9.2.3Key Competitors of the Company ............................................................ 162 9.2.4Financials ................................................................................................... 163 9.2.5Key Insights About the Financial Health of the Company ..................... 165 9.2.6Corporate Strategies ................................................................................. 165 9.2.6.1 Business Expansion ........................................................................................ 165 9.2.7Business Strategies .................................................................................. 165 7 All rights reserved at BIS Research Inc.

  8. 9.2.7.1 Product Approval ............................................................................................. 165 9.2.8SWOT Analysis .......................................................................................... 166 9.3 Grifols, S.A. .................................................................................................... 167 9.3.1Company Overview ................................................................................... 167 9.3.2Role of Grifols, S.A. in the Global Blood and Plasma Components Market ......................................................................................................... 167 9.3.3Key Competitors of the Company ............................................................ 168 9.3.4Financials ................................................................................................... 169 9.3.5Key Insights About the Financial Health of the Company ..................... 171 9.3.6Corporate Strategies ................................................................................. 171 9.3.6.1 Mergers and Acquisitions ................................................................................ 171 9.3.6.2 Synergistic Activities ........................................................................................ 171 9.3.6.3 Business Expansion and Funding ................................................................... 172 9.3.7Business Strategies .................................................................................. 172 9.3.7.1 Product Launch ................................................................................................ 172 9.3.8SWOT Analysis .......................................................................................... 173 9.4 ADMA Biologics, Inc. ..................................................................................... 174 9.4.1Company Overview ................................................................................... 174 GLOBAL BLOOD AND PLASMA COMPONENTS MARKET 9.4.2Role of ADMA Biologics, Inc. in the Global Blood and Plasma Components Market .................................................................................. 174 9.4.3Key Competitors of the Company ............................................................ 175 9.4.4Financials ................................................................................................... 176 9.4.5Key Insights About the Financial Health of the Company ..................... 177 9.4.6Corporate Strategies ................................................................................. 177 9.4.6.1 Synergistic Activities ........................................................................................ 177 9.4.7Business Strategies .................................................................................. 178 9.4.7.1 Product Launches ............................................................................................ 178 9.4.7.2 Product Approvals ........................................................................................... 178 8 All rights reserved at BIS Research Inc.

  9. 9.4.8SWOT Analysis .......................................................................................... 179 9.5 Takeda Pharmaceutical Company Limited .................................................. 180 9.5.1Company Overview ................................................................................... 180 9.5.2Role of Takeda Pharmaceutical Company Limited in the Global Blood and Plasma Components Market .................................................. 180 9.5.3Key Competitors of the Company ............................................................ 181 9.5.4Financials ................................................................................................... 182 9.5.5Key Insights About the Financial Health of the Company ..................... 183 9.5.6SWOT Analysis .......................................................................................... 184 9.6 GC Pharma ..................................................................................................... 185 9.6.1Company Overview ................................................................................... 185 9.6.2Role of GC Pharma in the Global Blood and Plasma Components Market ......................................................................................................... 185 9.6.3Key Competitors of the Company ............................................................ 186 9.6.4Corporate Strategies ................................................................................. 186 9.6.4.1 Synergistic Activities ........................................................................................ 186 9.6.4.2 Business Expansion ........................................................................................ 187 9.6.5SWOT Analysis .......................................................................................... 187 GLOBAL BLOOD AND PLASMA COMPONENTS MARKET 9.7 Octapharma AG ............................................................................................. 188 9.7.1Company Overview ................................................................................... 188 9.7.2Role of Octapharma AG in the Global Blood and Plasma Components Market .................................................................................. 188 9.7.3Key Competitors of the Company ............................................................ 189 9.7.4Financials ................................................................................................... 190 9.7.5Key Insights About the Financial Health of the Company ..................... 190 9.7.6Business Strategies .................................................................................. 191 9.7.6.1 Product Approval ............................................................................................. 191 9.7.7SWOT Analysis .......................................................................................... 192 9 All rights reserved at BIS Research Inc.

  10. 9.8 Kedrion S.p.A ................................................................................................. 193 9.8.1Company Overview ................................................................................... 193 9.8.2Role of Kedrion S.p.A in the Global Blood and Plasma Components Market ......................................................................................................... 193 9.8.3Key Competitors of the Company ............................................................ 194 9.8.4Financials ................................................................................................... 195 9.8.5Key Insights About the Financial Health of the Company ..................... 196 9.8.6Corporate Strategies ................................................................................. 196 9.8.6.1 Mergers and Acquisitions ................................................................................ 196 9.8.6.2 Synergistic Activities ........................................................................................ 197 9.8.7Business Strategies .................................................................................. 197 9.8.7.1 Product Approval ............................................................................................. 197 9.8.8SWOT Analysis .......................................................................................... 198 9.9 Emergent BioSolutions Inc. .......................................................................... 199 9.9.1Company Overview ................................................................................... 199 9.9.2Role of Emergent BioSolutions Inc. in the Global Blood and Plasma Components Market .................................................................................. 199 9.9.3Key Competitors of the Company ............................................................ 200 GLOBAL BLOOD AND PLASMA COMPONENTS MARKET 9.9.4Financials ................................................................................................... 201 9.9.5Key Insights About the Financial Health of the Company ..................... 203 9.9.6SWOT Analysis .......................................................................................... 204 9.10Bio Products Laboratory Ltd. ....................................................................... 205 9.10.1Company Overview ................................................................................... 205 9.10.2Role of Bio Products Laboratory Ltd. in the Global Blood and Plasma Components Market .................................................................... 205 9.10.3Key Competitors of the Company ............................................................ 206 9.10.4Corporate Strategies ................................................................................. 207 9.10.4.1 Synergistic Activities ........................................................................................ 207 10 All rights reserved at BIS Research Inc.

  11. 9.10.5Business Strategies .................................................................................. 207 9.10.5.1 Product Launch ................................................................................................ 207 9.10.6SWOT Analysis .......................................................................................... 208 9.11LFB S.A. .......................................................................................................... 209 9.11.1Company Overview ................................................................................... 209 9.11.2Role of LFB S.A. in Global Blood and Plasma Components Market ..... 209 9.11.3Key Competitors of the Company ............................................................ 210 9.11.4Corporate Strategies ................................................................................. 211 9.11.4.1 Synergistic Activities ........................................................................................ 211 9.11.5SWOT Analysis .......................................................................................... 211 9.12American red Cross ....................................................................................... 212 9.12.1Company Overview ................................................................................... 212 9.12.2Role of American Red Cross in the Global Blood and Plasma Components Market .................................................................................. 212 9.12.3Key Competitors of the Company ............................................................ 213 9.12.4Financials ................................................................................................... 214 9.12.5SWOT Analysis .......................................................................................... 215 9.13Versiti, Inc. ...................................................................................................... 216 GLOBAL BLOOD AND PLASMA COMPONENTS MARKET 9.13.1Company Overview ................................................................................... 216 9.13.2Role of Versiti, Inc. in the Global Blood and Plasma Components Market ......................................................................................................... 216 9.13.3Key Competitors of the Company ............................................................ 217 9.13.4SWOT Analysis .......................................................................................... 217 9.14Blood Centers of America ............................................................................. 218 9.14.1Company Overview ................................................................................... 218 9.14.2Role of Blood Centers of America in the Global Blood and Plasma Components Market .................................................................................. 218 9.14.3Key Customers of the Company .............................................................. 219 11 All rights reserved at BIS Research Inc.

  12. 9.14.4Key Competitors of the Company ............................................................ 219 9.14.5SWOT Analysis .......................................................................................... 220 9.15Carter BloodCare ........................................................................................... 221 9.15.1Company Overview ................................................................................... 221 9.15.2Role of Carter BloodCare in the Global Blood and Plasma Components Market .................................................................................. 221 9.15.3Key Competitors of the Company ............................................................ 222 9.15.4SWOT Analysis .......................................................................................... 222 9.16Memorial Blood Centers ............................................................................... 223 9.16.1Company Overview ................................................................................... 223 9.16.2Role of Memorial Blood Centers in the Global Blood and Plasma Components Market .................................................................................. 223 9.16.3Key Competitors of the Company ............................................................ 224 9.16.4SWOT Analysis .......................................................................................... 225 GLOBAL BLOOD AND PLASMA COMPONENTS MARKET 12 All rights reserved at BIS Research Inc.

  13. List of Figures Figure 1:Global Blood and Plasma Components Market, $Billion, 2020 and 2031 Figure 2:Impact Analysis of Market Drivers and Market Restraints on the Global Blood and Plasma Components Market Figure 3:Global Blood and Plasma Components Market Segmentation Figure 4:Global Blood and Plasma Components Market (by Product), 2020 and 2031 Figure 5:Global Blood and Plasma Components Market (by Application), 2020 and 2031 Figure 6:Global Blood and Plasma Components Market (by End User), 2020 and 2031 Figure 7:Global Blood and Plasma Components Services Market Snapshot (by Region) Figure 8:Global Blood and Plasma Components Market: Segmentation Figure 9:Global Blood and Plasma Components Market: Methodology Figure 10:Primary Research Methodology Figure 11:Bottom-Up Approach (Segment-Wise Analysis) Figure 12:Top-Down Approach (Segment-Wise Analysis) Figure 13:Global Blood and Plasma Components Market, $Billion, 2020-2031 Figure 14:Workflow of Biologics License Application (BLA) Process Figure 15:China’s Regulatory Institutions under NMPA Figure 16:Workflow of Drug Approval Process in Japan Figure 17:Schematic Representation of Blood Supply Chain Figure 18:Blood and Blood Components Storage Requirements GLOBAL BLOOD AND PLASMA COMPONENTS MARKET Figure 19:Global Blood and Plasma Components Market: COVID-19 Impact Analysis Figure 20:Number of Patients with Bleeding Disorders, 2016-2020 Figure 21:Comparison of Manufacturing Process of Plasma-Derived Medicinal Products and Traditional Pharmaceutical Products Figure 22:Share of Key Developments, January 2018-January 2022 Figure 23:Share of Mergers and Acquisitions (by Company), January 2018-January 2022 Figure 24:Share of Synergistic Activities (by Company), January 2018-January2022 Figure 25:Share of Business Expansion, Funding, and Reimbursement Activities (by Company), January 2018-January 2022 Figure 26:Share of Product Launches (by Company), January 2018-January 2022 Figure 27:Share of Product Approvals (by Company), January 2018-January 2022 13 All rights reserved at BIS Research Inc.

  14. Figure 28:Market Share Analysis of Global Blood and Plasma Components Market, by Company (2019 and 2020) Figure 29:Growth-Share Analysis for Global Blood and Plasma Components Market (by Company), 2020 Figure 30:Global Blood and Plasma Components Market Segmentation (by Product) Figure 31:Global Blood and Plasma Components Market (by Transfusion Market), $Billion, 2020-2031 Figure 32:Global Blood and Plasma Components Market (by Transfusion Market), 2020 and 2031 Figure 33:Global Blood and Plasma Components Market (Packed Red Blood Cells), $Billion, 2020-2031 Figure 34:Global Blood and Plasma Components Market (Platelet Products), $Billion, 2020-2031 Figure 35:Components of Plasma Figure 36:Global Blood and Plasma Components Market (Frozen Plasma), $Billion, 2020-2031 Figure 37:Global Blood and Plasma Components Market (by Plasma-Derived Products, $Billion, 2020- 2031 Figure 38:Global Blood and Plasma Components Market (by Plasma-Derived Products), 2020 and 2031 Figure 39:Global Blood and Plasma Components Market (Immunoglobulins), $Billion, 2020-2031 Figure 40:Global Blood and Plasma Components Market (by Immunoglobulins), 2020 and 2031 Figure 41:Global Blood and Plasma Components Market (Intravenous Immunoglobulins), $Billion, 2020- 2031 Figure 42:Global Blood and Plasma Components Market (Subcutaneous Immunoglobulins), $Billion, 2020-2031 Figure 43:Global Blood and Plasma Components Market (Other Immunoglobulins), $Billion, 2020-2031 Figure 44:Coagulation Factor Concentrates Market Segmentation Figure 45:Global Blood and Plasma Components Market (by Coagulation Factor Concentrates), $Billion, 2020-2031 GLOBAL BLOOD AND PLASMA COMPONENTS MARKET Figure 46:Global Blood and Plasma Components Market (by Coagulation Factor Concentrates), 2020 and 2031 Figure 47:Global Blood and Plasma Components Market (Coagulation Factor VIII Concentrate), $Billion, 2020-2031 Figure 48:Global Blood and Plasma Components Market (Coagulation Factor IX Concentrate), $Billion, 2020-2031 Figure 49:Global Blood and Plasma Components Market (von Willebrand Factor), $Billion, 2020-2031 Figure 50:Global Blood and Plasma Components Market (Prothrombin Complex Concentrates), $Billion, 2020-2031 Figure 51:Global Blood and Plasma Components Market (Coagulation Factor XIII Concentrate), $Billion, 2020-2031 Figure 52:Global Blood and Plasma Components Market (Albumins), $Billion, 2020-2031 14 All rights reserved at BIS Research Inc.

  15. Figure 53:Global Blood and Plasma Components Market (Proteinase Inhibitors), $Billion, 2020-2031 Figure 54:Global Blood and Plasma Components Market (Other Blood Derivatives), $Billion, 2020-2031 Figure 55:Global Blood and Plasma Components Market Segmentation (by Application) Figure 56:Global Blood and Plasma Components Market (by Application), 2020 and 2031 Figure 57:Global Blood and Plasma Components Market (by Hematology), $Billion, 2020-2031 Figure 58:Global Blood and Plasma Components Market (by Hemoglobinopathy), $Billion, 2020-2031 Figure 59:Types of Thalassemia Figure 60:Global Blood and Plasma Components Market (Thalassemia), $Billion, 2020-2031 Figure 61:Common Types of Sickle Cell Disease (SCD) Figure 62:Global Blood and Plasma Components Market (Sickle Cell Disease), $Billion, 2020-2031 Figure 63:Global Blood and Plasma Components Market (Platelet Refractoriness), $Billion, 2020-2031 Figure 64:Global Blood and Plasma Components Market (Hematologic Malignancies Management), $Billion, 2020-2031 Figure 65:Global Blood and Plasma Components Market (by Coagulopathy), $Billion, 2020-2031 Figure 66:Types of Hemophilia Figure 67:Global Blood and Plasma Components Market (Hemophilia), $Billion, 2020-2031 Figure 68:Types of Von Willebrand’s Disease (vWD) Figure 69:Global Blood and Plasma Components Market (von Willebrand Disease), $Billion, 2020-2031 Figure 70:Classification of Thrombosis Figure 71:Global Blood and Plasma Components Market (Thrombosis), $Billion, 2020-2031 Figure 72:Different Causes of Thrombocytopenia GLOBAL BLOOD AND PLASMA COMPONENTS MARKET Figure 73:Global Blood and Plasma Components Market (Thrombocytopenia), $Billion, 2020-2031 Figure 74:Global Blood and Plasma Components Market (Solid Tumor Management), $Billion, 2020-2031 Figure 75:Global Blood and Plasma Components Market (Others), $Billion, 2020-2031 Figure 76:Global Blood and Plasma Components Market Segmentation (by End User) Figure 77:Global Blood and Plasma Components Market (by End User), 2020 and 2031 Figure 78:Global Blood and Plasma Components Market (Hospitals and Specialty Clinics), $Billion, 2020- 2031 Figure 79:Global Blood and Plasma Components Market (Research Institutions), $Billion, 2020-2031 Figure 80:Global Blood and Plasma Components Market (Diagnostics Laboratories), $Billion, 2020-2031 Figure 81:Global Blood and Plasma Components Market (Other End Users), $Billion, 2021-2031 Figure 82:Global Blood and Plasma Components Services Market Snapshot (by Region) Figure 83:Global Blood and Plasma Components Market (by Region), 2020 and 2031 15 All rights reserved at BIS Research Inc.

  16. Figure 84:North America Blood and Plasma Components Market, $Billion, 2020-2031 Figure 85:U.S. Blood and Plasma Components Market, $Billion, 2020-2031 Figure 86:Canada Blood and Plasma Components Market, $Billion, 2020-2031 Figure 87:Europe Blood and Plasma Components Market, $Billion, 2020-2031 Figure 88:Germany Blood and Plasma Components Market, $Billion, 2020-2031 Figure 89:U.K. Blood and Plasma Components Market, $Billion, 2020-2031 Figure 90:France Blood and Plasma Components Market, $Billion, 2020-2031 Figure 91:Italy Blood and Plasma Components Market, $Billion, 2020-2031 Figure 92:Spain Blood and Plasma Components Market, $Billion, 2020-2031 Figure 93:Rest-of-Europe Blood and Plasma Components Market, $Billion, 2020-2031 Figure 94:Asia-Pacific Blood and Plasma Components Market, $Billion, 2020-2031 Figure 95:China Blood and Plasma Components Market, $Billion, 2020-2031 Figure 96:India Blood and Plasma Components Market, $Billion, 2020-2031 Figure 97:Japan Blood and Plasma Components Market, $Billion, 2020-2031 Figure 98:Australia Blood and Plasma Components Market, $Billion, 2020-2031 Figure 99:South Korea Blood and Plasma Components Market, $Billion, 2020-2031 Figure 100:Singapore Blood and Plasma Components Market, $Billion, 2020-2031 Figure 101:Rest-of-Asia-Pacific Blood and Plasma Components Market, $Billion, 2020-2031 Figure 102:Rest-of-the-World Blood and Plasma Components Market, $Billion, 2020-2031 Figure 103:Total Number of Companies Profiled Figure 104:Global Blood and Plasma Components Market, Company Profile Overview GLOBAL BLOOD AND PLASMA COMPONENTS MARKET Figure 105:CSL Limited: Product Portfolio Figure 106:CSL Limited: Overall Financials, $Million, 2018-2020 Figure 107:CSL Limited: Revenue (by Segment), $Million, 2018-2020 Figure 108:CSL Limited: Revenue (by Region), $Million, 2018-2020 Figure 109:CSL Limited: R&D Expenditure, $Million, 2018-2020 Figure 110:CSL Limited: SWOT Analysis Figure 111:Grifols, S.A.: Product Portfolio Figure 112:Grifols, S.A.: Overall Financials, $Million, 2018-2020 Figure 113:Grifols, S.A.: Revenue (by Segment), $Million, 2018-2020 Figure 114:Grifols, S.A.: Revenue (by Region), $Million, 2018-2020 Figure 115:Grifols, S.A.: R&D Expenditure, $Million, 2018-2020 Figure 116:Grifols, S.A.: SWOT Analysis 16 All rights reserved at BIS Research Inc.

  17. Figure 117:ADMA Biologics, Inc.: Product Portfolio Figure 118:ADMA Biologics, Inc.: Overall Financials, $Million, 2018-2020 Figure 119:ADMA Biologics, Inc.: Revenue (by Segment), $Million, 2018-2020 Figure 120:ADMA Biologics, Inc.: R&D Expenditure, $Million, 2018-2020 Figure 121:ADMA Biologics, Inc.: SWOT Analysis Figure 122:Takeda Pharmaceutical Company Limited: Product Portfolio Figure 123:Takeda Pharmaceutical Company Limited: Overall Financials, $Million, 2018-2020 Figure 124:Takeda Pharmaceutical Company Limited: Revenue (by Region), $Million, 2018-2020 Figure 125:Takeda Pharmaceutical Company Limited: R&D Expenditure, $Million, 2018-2020 Figure 126:Takeda Pharmaceutical Company Limited: SWOT Analysis Figure 127:GC Pharma: Product Portfolio Figure 128:GC Pharma: SWOT Analysis Figure 129:Octapharma AG: Product Portfolio Figure 130:Octapharma AG: Overall Financials, $Million, 2018-2020 Figure 131:Octapharma AG: R&D Expenditure, $Million, 2018-2020 Figure 132:Octapharma AG: SWOT Analysis Figure 133:Product Portfolio Figure 134:Kedrion S.p.A: Overall Financials, $Million, 2018-2020 Figure 135:Kedrion S.p.A: Revenue (by Region), $Million, 2018-2020 Figure 136:Kedrion S.p.A: R&D Expenditure, $Million, 2018-2020 Figure 137:Kedrion S.p.A.: SWOT Analysis GLOBAL BLOOD AND PLASMA COMPONENTS MARKET Figure 138:Emergent BioSolutions Inc.: Product Portfolio Figure 139:Emergent BioSolutions Inc.: Overall Financials, $Million, 2018-2020 Figure 140:Emergent BioSolutions Inc.: Revenue (by Segment), $Million, 2018-2020 Figure 141:Emergent BioSolutions Inc.: Revenue (by Region), $Million, 2018-2020 Figure 142:Emergent BioSolutions Inc.: R&D Expenditure, $Million, 2018-2020 Figure 143:Emergent BioSolutions Inc.: SWOT Analysis Figure 144:Bio Products Laboratory Ltd.: Product Portfolio Figure 145:Bio Products Laboratory Ltd.: SWOT Analysis Figure 146:LFB S.A.: Product Portfolio Figure 147:LFB S.A.: SWOT Analysis Figure 148:American Red Cross: Product Portfolio Figure 149:American Red Cross: Overall Financials, $Million, 2018-2020 17 All rights reserved at BIS Research Inc.

  18. Figure 150:American Red Cross: SWOT Analysis Figure 151:Versiti, Inc.: Product Portfolio Figure 152:Versiti, Inc.: SWOT Analysis Figure 153:Blood Centers of America: Product Portfolio Figure 154:Blood Centers of America: SWOT Analysis Figure 155:Carter BloodCare: Product Portfolio Figure 156:Carter BloodCare: SWOT Analysis Figure 157:Memorial Blood Centers: Product Portfolio Figure 158:Memorial Blood Centers: SWOT Analysis GLOBAL BLOOD AND PLASMA COMPONENTS MARKET 18 All rights reserved at BIS Research Inc.

  19. List of Tables Table 1: Differences between Neutrophils, Eosinophils, and Basophils Table 2: Major Events in the Use of Blood and Plasma Components Table 3: Likert Scale Table 4: Impact Analysis of Market Drivers Table 5: Impact Analysis of Market Restraints Table 6: List of Acute Adverse Reactions and Delayed Adverse Reactions Table 7: List of Companies Offering Intravenous Immunoglobulins (IVIGs) Table 8: List of Companies Offering Subcutaneous Immunoglobulins (SCIGs) Table 9: List of Companies Offering Intramuscular Immunoglobulins (IMIG) Table 10:List of Companies Offering Coagulation Factor VIII Concentrate Table 11:List of Companies Offering Coagulation Factor IX Concentrate Table 12:List of Companies Offering von Willebrand Factor Table 13:List of Key Competitors of CSL Limited Table 14:List of Key Competitors of Grifols, S.A. Table 15:List of Key Competitors of ADMA Biologics, Inc. Table 16:List of Key Competitors of Takeda Pharmaceutical Company Limited Table 17:List of Key Competitors of GC Pharma Table 18:List of Key Competitors of Octapharma AG Table 19:List of Key Competitors of Kedrion S.p.A GLOBAL BLOOD AND PLASMA COMPONENTS MARKET Table 20:List of Key Competitors of Emergent BioSolutions Inc. Table 21:List of Key Competitors of Bio Products Laboratory Ltd. Table 22:List of Key Competitors of LFB S.A. Table 23:List of Key Competitors of American Red Cross Table 24:List of Key Competitors of Versiti, Inc. Table 25:List of Key Customers of Blood Centers of America Table 26:List of Key Competitors of Blood Centers of America Table 27:List of Key Competitors of Carter BloodCare Table 28:List of Key Competitors of Memorial Blood Centers 19 All rights reserved at BIS Research Inc.

  20. BIS Research Offerings: We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s digital age. We have the vision to be a leading and preferred knowledge partner for corporates and institutions worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other innovative solutions. Know More Know More Know More GLOBAL BLOOD AND PLASMA COMPONENTS MARKET Know More 20 All rights reserved at BIS Research Inc.

  21. Disclaimer BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published, or reproduced, in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce Information in legal proceedings. Market reports are based on expectations, estimates, and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to market fluctuations and business, economic and competitive uncertainties, and contingencies. For more details regarding permission, please contact us: Email: sales@bisresearch.com Tel: +1 510 404 8135 GLOBAL BLOOD AND PLASMA COMPONENTS MARKET 21 All rights reserved at BIS Research Inc.

  22. GLOBAL BLOOD AND PLASMA COMPONENTS MARKET BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686 E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135 Global Delivery Center Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway, Sector 126, Noida, U.P., 201303, India Tel: +91 120 4261540 / 4261544 22 www.bisresearch.com All rights reserved at BIS Research Inc.

More Related